This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with repotrectinib. The study will describe how often side effects occur during treatment, with special attention to central nervous system disorders, interstitial lung disease, and fractures.
Study Type
OBSERVATIONAL
Enrollment
20
As per product label
CMIC Co., Ltd.
Minato-ku, Tokyo, Japan
RECRUITINGEPS Corporation
Tokyo, Japan
RECRUITINGNumber of participants with 1 or more adverse events (AEs)
Time frame: Up to week 104
Number of participants with 1 or more serious adverse events (SAEs)
Time frame: Up to week 104
Number of participants with adverse events by system organ class (including central nervous system disorders, interstitial lung disease, and fractures)
Time frame: Up to week 104
Number of participants with adverse events (AEs) leading to treatment modification (interruption, dose reduction, or discontinuation)
Time frame: Up to week 104
Number of participants with each adverse event outcome category (resolved, resolving, not resolved, resolved with sequelae, death, unknown)
Time frame: Up to week 104
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.